Previous 10 | Next 10 |
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its third quarter 2021 financial results before the market opens on Thursday, November 4, 2021. In conjunction with the release, the company will host a conference call and webcast...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the appointment of Robert Bruce to the newly created position of Vice President of Reimbursement. “We are very pleased to welcome Bob and his impressive public and private payer reimbur...
What do the most successful investors do when their favorite stocks tank? If you're Cathie Wood, founder, and CEO of ARK Invest, you keep buying more. Shares of life-science equipment manufacturer Berkeley Lights (NASDAQ: BLI) took a hit last week, and two ARK Invest ETFs qu...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP) has issued a new task order under its current contract with the company, with a value of up ...
I don't know about you, but the day after Labor Day has never been a very productive one. The same cannot be said for ARK Invest CEO and founder Cathie Wood. Yesterday, the collection of exchange-traded funds she manages were just as busy as ever. Wood confidently bought some healthcare...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the Morgan Stanley 19 th Annual Global Healthcare Conference on Thursday, September 9, 2021 at 3:30 p.m. Eastern Time. About Personalis, Inc....
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will relocate both its corporate headquarters and the Personalis Clinical Laboratory from Menlo Park to 6600 Dumbarton Circle in Fremont. The new facility will support the Company...
The following slide deck was published by Personalis, Inc. in conjunction with this event. For further details see: Personalis (PSNL) Investor Presentation - Slideshow
Personalis, Inc. (PSNL) Q2 2021 Earnings Conference Call August 04, 2021 5:30 PM ET Company Participants Caroline Corner – Investor Relations John West – President and Chief Executive Officer Aaron Tachibana – Chief Financial Officer Conference Call Participants Kevin DeG...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer and population sequencing, today reported financial results for the second quarter ended June 30, 2021. Second Quarter and Recent Highlights Record quarterly revenue of $21.7 million in the second qu...
News, Short Squeeze, Breakout and More Instantly...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2024 financial results on Wednesday, August 7, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tum...